Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Antibody therapeutics have revolutionized the treatment of cancer over the past two
decades. Antibodies that specifically bind tumor surface antigens can be effective …

Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the
field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues …

Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-
molecule payloads. ADCs demonstrate specific cell killing in clinic, but the basis of their …

Plants, marine organisms, and microorganisms have evolved complex chemical defense
and signaling systems that are designed to protect them from predators and provide other …

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the
potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic …

Antibody–drug conjugates (ADC) are designed to selectively bind to tumor antigens via the
antibody and release their cytotoxic payload upon internalization. Controllable payload …

Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting
antigens on tumor cells, represent promising novel agents for the treatment of malignant …

A majority of ovarian and non–small cell lung adenocarcinoma cancers overexpress folate
receptor α (FRα). Here, we report the development of an anti-FRα antibody–drug conjugate …

Abstract Antibody–drug conjugates (ADCs), which combine the specificity, favorable
pharmacokinetics, and biodistribution of a monoclonal antibody (mAb) with the cytotoxic …